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1. Introduction
Molecular imaging techniques depend upon molecular mechanisms operative in vivo. This
imaging technique encompasses the visualization, characterization and measurement of
biological processes at the molecular and cellular levels in humans and other living systems
[1]. The techniques used include Positron Emission Tomography – Computed Tomography
(PET-CT), nuclear medicine, Magnetic Resonance Imaging (MRI), Magnetic Resonance
Spectroscopy (MRS), optical imaging and ultrasound.
There are escalating evidences in the published data that discussed the advantages of inte‐
grated molecular imaging technique as an accurate tool in localizing abnormal metabolic
alteration and serve as a potential role as an invasive surrogate biomarker for various disease
entities [2,3,4,5]. It also plays an increasingly fundamental role in drug discovery and early
development in humans. The evolution of molecular imaging tool in specific PET-CT has
impacted the use of molecular imaging technique in many altered cellular mechanism. In
particular, PET which was introduced in the 1970 s is capable of quantifying individual changes
on the different pathology that underpin the biological reprogramming in abnormal cells [6].
Intensive research activities in various PET applications gradually evolved to its clinical use
first in neuropsychiatric disorders and cardiology, then in oncology.
Molecular  imaging  provides  the  key  to  the  future  of  personalized  medicine,  which  in‐
volves diagnosing, treating and monitoring patients based on their individual makeup. The
amelioration in its technique has braced the one-stop-imaging strategy in various disease
entities as a tool for disease localization, prediction and treatment monitoring. For the purpose
of the discussion in this chapter, we highlight the integrated molecular imaging technique
PET-CT employing flurodeoxyglucose (FDG) as a standard of care utility in various disease
pathology.
© 2013 Saad et al.; licensee InTech. This is an open access article distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use,
distribution, and reproduction in any medium, provided the original work is properly cited.
2. Types of molecular imaging techniques
Molecular imaging, a new discipline in biomedical research has increasingly become a vital
tool in disease diagnostic frontier. It offers an excellent visualization, characterization and
quantification of biologic process taking place at the cellular and sub-cellular levels. As of now,
there are four main categories of molecular imaging modalities; ultrasound, optical imaging,
magnetic resonance imaging (MRI), and nuclear imaging techniques (Table 1). Bonekamp [7]
in his paper reported that the selection of the imaging modality often is determined based on
the temporal and spatial resolution, field of view, sensitivity of the imaging system, depth of
the biological process, the molecular or cellular process to image, and the availability of suitable
probes and labels than can be delivered to the imaging target. An overview of mechanism
behind each of the modalities will be covered in the subsequent section.
Molecular Imaging Modalities
Single modality Multimodalities
Ultrasound PET-CT
MRI SPECT-CT
PET PET-MRI
SPECT
Optical Imaging
Table 1. Types of Molecular Imaging Modalities
2.1. Ultrasound
Ultrasound imaging has been used for over 20 years. It uses high-frequency sound waves to
view soft tissues such as muscles and internal organs inside the body. As the image of the
ultrasound is captured in real-time, it enables the physician to see the movement of the body’s
internal organs as well as blood flowing through the vessels. In an ultrasound exam, a hand-
held transducer is placed against the skin. The transducer sends out high frequency sound
waves that reflect off the body structures. As sound waves directed through the body bounce
back when they encounter different tissues, echoes are measured with the help of a computer
and are converted into real-time images of organs and tissues. The image captured is based
on the frequency and strength of the sound signal and the time it takes to return from the
patient to the transducer [8].
2.2. Optical imaging
In optical imaging, light-producing proteins are designed to attach to specific molecules such
as brain chemicals or molecules on the surface of cancer cells [9]. Highly sensitive detectors
are employed for detection of low levels of light emitted by specific molecules from inside the
body. The two major types of optical imaging are bioluminescent imaging and fluorescence
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imaging. Bioluminescent imaging uses a natural light-emitting protein to trace the movement
of certain cells or to identify the location of specific chemical reactions within the body. In
contrast, fluorescence imaging uses proteins that produce light when activated by an external
light source such as laser.
2.3. Magnetic resonance imaging
Magnetic resonance imaging or popularly known as MRI is an imaging technique used mainly
in medical settings to produce high quality images of inside human body. Theoretically, the
mechanism behind MRI is based on the principles of nuclear magnetic resonance (NMR), a
spectroscopic technique used by scientist to obtain microscopic chemical and physical
information about molecules [10]. MRI scanner has a tube surrounded by a giant circular
magnet. During routine examination of MRI, patient is placed on a moveable bed that is
inserted into the magnet. The presence of magnet creates a strong magnetic field that aligns
the protons of hydrogen atoms, which are then exposed to a beam of radio waves [11]. This
spins various protons of the body, and produces a faint signal that is detected by the receiver
portion of the MRI scanner. The receiver information is processed by a computer and an image
is then produced.
2.4. Nuclear Imaging
Nuclear imaging or also called as radionuclide scanning provides an effective diagnostic tools
for the radiologists as it shows not only the structure of an organ but also the function of the
organ. Nuclear imaging routine uses small amounts of radioactive material, or tracer for
diagnostic purpose. Radioactive tracer used in nuclear imaging is normally a specifically
targeted probe. It could be antibodies, ligands or substrates to specifically interact with protein
targets in particular cells or sub cellular compartments. These interactions are based on either
receptor-radioligand binding or enzyme mediated trapping of a radio labeled substrate [12].
Radioactive tracers used in nuclear imaging are in most cases is administered into a vein and
some are given orally. After an administration of radioactive tracers, patient is required to rest
for a certain period to allow distribution of radioactive tracer in the body. In the end, for
imaging purpose, a specialized gamma camera is used to detect the radiation throughout the
body. Most commonly used techniques in nuclear imaging are positron emission tomography
(PET) and single photon emission computed tomography (SPECT).
2.4.1. Positron Emission Tomography (PET)
Positron emission tomography or known as ‘PET’ is a rapidly developing nuclear imaging
technique, with a clinical role that now exceeds almost 15 years [13].  It  is a quantitative
tomographic imaging technique which produces cross-sectional images that are composites
of volume elements [14]. The signal intensity for PET images in each voxel is dependent upon
the activity of radionuclide tagged with radioactive tracer which intravenously adminis‐
tered at the earlier stage before the scanning takes place. A scanner which usually called PET
scanner employs a gamma photon coincidence detection system designed for oppositely
directed  annihilation  photons  emitted  indirectly  by  the  positron  decay  of  PET radionu‐
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clides. This logic allows acquisition of images that are quantitative three dimensional (3-D)
maps of radiolabeled tracers in tissue. The most commonly used PET radioactive tracer is
the glucose derivative, 2-[18F]fluoro-2-deoxy-D-glucose or commercially known as [18F]FDG,
with numerous other tracers under development capable of highlighting a broad range of
organ and tissue metabolic functions. In a large meta-analysis, PET was shown to change
management in 30% of patients [15].
2.4.2. Single Photon Emission Computed Tomography (SPECT)
Similar to PET, single photon emission computed tomography (SPECT) also uses a radioactive
tracer that is administered to the patient and a scanner to record data that a computer constructs
into two or three dimensional images. However, in another note, SPECT technique employs a
gamma camera that rotates around the patient to detect a radioactive tracer in the body. In
contrast to PET which employs shorter half-lived tracers as opposed to the SPECT tracers [16].
If a tumor is present, the antibodies will stick to it and thus allow for detection of tumorous
cells. For better understanding on strength and weakness of each imaging modalities, Table
2 below provides a summary of the imaging techniques with its respective strength and
weakness.
Imaging modality Electro magnetic
radiation spectrum
Advantages Disadvantages
Ultrasound High-frequency sound Real time and low cost Limited spatial resolution, mostly
morphologic although targeted
micro bubbles under development
Optical
bioluminescence
imaging
Visible light Highest sensitivity, quick, easy,
low cost and relatively high
throughput
Low spatial resolution, current 2-D
imaging only, relatively surface
weighted, limited translational
research
Optical
fluorescence
imaging
Visible light or near-
infrared
High sensitivity, detects
fluorochrome in live and dead
cells
Relatively low spatial resolution,
relatively surface weighted
Magnetic
resonance
imaging (MRI)
Radio waves Highest spatial resolution,
combines morphologic and
functional imaging
Relatively low sensitivity, long scan
and post processing time, mass
quantity of probe may be needed
Positron Emission
Tomography (PET)
High energy gamma
rays
High sensitivity, shorter time scan,
enable quantitative analysis
PET cyclotron or generator
needed, relatively low spatial
resolution
Single photon
emission
computed
tomography
(SPECT)
Lower energy gamma
rays
Many molecular probes available,
can image multiple probes
simultaneously, may be adapted
to clinical imaging system
Relatively low spatial resolution,
high radiation to subjects due to
longer tracer half-life’s, non-
quantitative tool,
Longer scanning time
Table 2. Key strength and weakness of the main available imaging modalities used in molecular imaging [12, 16]
Selected Topics on Computed Tomography18
3. Integrated molecular imaging techniques (FDG PET-CT)
The astonishing achievement of the molecular imaging technique rely on its ability to signal
altered metabolism in a targeted pathological cells whereby two imaging modalities are
integrated in a single setting (multimodality imaging technique/integrated imaging) i.e. PET-
CT, SPECT-CT, PET-MRI. It includes two- or three-dimensional imaging as well as quantifi‐
cation over time (Figure 1). Largely independent of structural disturbances, integrated
molecular imaging techniques increasingly offer high spatial resolution, but more particularly,
high contrast. Minute quantities of radioactive materials, chosen because of their ability to
participate in biological processes of interest, can provide highly sensitive indications of body
function in health and disease. Therefore, disordered metabolism or physiology can be
detected with high sensitivity and the anatomical distribution of abnormality can be deter‐
mined with greater precision than the conventional technique (Table 3). The conventional
imaging techniques i.e. computed tomography (CT) or standalone nuclear medicine technique
– single positron emission tomography (SPECT) are relatively unpopular in a current scenario
given their limitations to only evaluating the structural changes or functional changes
disjointedly.
Figure 1. PET-CT image display on the Syngo console panel showing series of CT, PET and fused images.
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Published data
Sensitivity versus Specificity (%)
PET-CT CT
Niikura N et al
Metastatic breast cancer[2] 97.4 versus 91.2 85.9 versus 67.3
Kim SK et al
(solitary pulmonary lesion)[3] 97.0 versus 85 93.0 versus 31.0
Pim A. et al
(malignant lymphoma)[4] 100.0versus 95.0 91.0 versus 96.0
Ozkan E et al
(colorectal cancer recurrence) [5] 98.0 versus 85.0 73.0 versus 86.0
Table 3. Data shows the accuracy of the PET-Ct and the CT in the evaluation of various tumors
3.1. FDG PET-CT and Standard Uptake Value (SUV)
The imaging of the alteration of the glucose metabolism, as reflected by cellular uptake and
trapping of the glucose analog 18F-FDG can suffice a response assessment that is both accurate
and contemporaneously than that provided by standard morphologic imaging. Quantitative
evaluation of FDG PET images provides quantitative data in the form of the standardized
uptake value (SUV). This is an uptake measurement that provides a mean of comparison of
FDG uptake between different lesions. Measurement of SUV requires attenuation correction
to avoid the variability in FDG uptake due to the differences in tumor habitus within the body.
This value normalizes the tumor FDG uptake with the FDG injected activity and the body
weight [17]. The cut-off value of 2.5 in differentiating malignant to benign is at large limited
due to varied tumor histological characteristic in malignant tumor [18)
3.2. FDG PET-CT and radiation issues
Being a glucose analogue, 2-[18F]fluoro-2-deoxy-D-glucose or commonly known as 18F-FDG,
is the most commonly used positron emitting radiopharmaceutical in PET examination. The
preparation of 18F-FDG involves the production of radioisotope fluorine-18 to tag with glucose
derivative. Fluorine-18, a positron emitters, emits gamma energy of 511 keV and due to
positron annihilation, it emits total energy of 1022 keV. This is almost 10 times higher than
conventional X-ray radiation. Therefore, it possesses high activity and dose exposure to
radiation workers and patients.
However, the radiation exposure could be outweighed due to its benefit to the patient. This is
in compliance with the International Commission on Radiological Protection (ICRP) which
recommended three elements in the system of dose limitation [19]. The three elements are;
justification, optimization and dose limitation. Justification means that any propose examina‐
tion that may cause exposure to the patients should yield a sufficient benefit to the patients to
justify the risk incurred by the radiation exposure. This element is based on the assumption
that any radiation exposure, either it is in small dose, carries with it a certain level of risk that
is proportional to the level of exposure. The second element is optimization, which is also
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known as the practice of ALARA (as low as reasonably achievable). This by all means, the
radiation exposures resulting from the examination or preparation of radiopharmaceuticals
must be reduced to the lowest level possible, considering the cost of such a reduction in dose.
The third element in ICRP recommendation is dose limitation. The dose limits are normally
imposed by the local regulatory agencies.
To accommodate a dose exposure at minimum, certain laboratory technique can be improved
when dealing with radioactive materials. The use of teleplier, long tong or robotic arms can
maximize the distance between the radioactive material and personnel. This directly reduces
the dose expose to the radiation worker [20]. In the administrative and procedure control aspect,
the introduction of automated dose dispensing will replace the manual dose dispensing activity
performs by the radiation worker to eliminate receiving of unnecessary exposure. The rota‐
tion between personnel involves in preparation of radiopharmaceutical and examination also
provides an alternative way to reduce high dose expose. Nevertheless, PET utilizes 18F-FDG as
a radiotracer carries a low absorbed dose to patient estimated at approximately 7 mSv. The
radiation (x rays) from our diagnostic CT protocol ranges from 8mSv to 16 mSv. The new
technology 64 multislice CT technique is equipped with the dual focal spot that ensures more
image yields  without  increased in the total  radiation dose.  The modulated tube current
adaptation of higher multislice CT scanner (64 and above) technique as offered by many vendors
is capable of reducing patient dose up to 20% as compared to the lower 16 multislice of the same
kind. [21,22]. In a nutshell, even though the use of molecular imaging modalities possesses risk
onto the patients and radiation workers, but the purpose of examination outweigh the implica‐
tion of the dose receive and it offers benefit for diagnosis and treatment purpose.
4. Molecular imaging in clinical application
4.1. Utility of integrated molecular imaging (PET-CT) in oncology
Oncology is now the most important application of molecular imaging techniques i.e. PET [23].
In oncology, PET can be used for signaling biological process that underpins pathological
reprogramming that  promotes  carcinogenesis.  Among the  important  signaling processes
involved are the altered glucose metabolism, amino acid metabolism, cell membranes metabo‐
lism and cell proliferation (Figure 2). Leveraging the rapidly increasing pace of technological
and scientific innovation in molecular biology, there has been a surge in the understanding of
the key drivers of malignant transformation. An important key driver in malignant transforma‐
tion is the altered glucose metabolism whereby a glucose analog or Flurodeoxyglucose (FDG)
has been utilized as a popular ligand used in labeling the tumor targets.
In vivo, intense FDG uptake and metabolism of glucose, a frequent characteristic of most cancer
cells, is associated with an alteration in the intrinsic energy metabolism causing a shift from
oxidative phosphorylation to aerobic glycolysis, a change referred to as the Warburg effect [24].
Otto Warburg, working in Germany in the 1920s, discovered that cancer cells have a character‐
istically increased glycolysis even under aerobic conditions. Because glycolysis is considera‐
bly less efficient than oxidative phosphorylation at producing adenosine triphosphate (ATP),
the tumor cell requires acceleration in the rate of glucose uptake and use. Given the known
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natural behaviours of tumors, [18F] FDG accumulation in tumors is used as index of increased
glucose metabolism and as a marker of tumor viability for which, the degree of [18F] FDG uptake
usually reflects tumor aggressiveness. The kinetics of the FDG tracers is similar to glucose. It
passes through the brain-blood barrier and is phosphorylated intracellularly in a process
analogous to the glucose. The phosphorylized FDG compound does not enter in the Krebs cycle,
thence it is effectively trapped. FDG as a molecular marker in signifying the molecular path‐
ways of each cancer types in different types of cancer of the study. Malignant cells have increased
facilitated glucose transport and up regulation of hexokinase activity, and hence tumors can be
identified by regions of increased glucose utilization [25]. The PET tracer FDG, a glucose analog,
is used to image glucose metabolism in patients. Focal areas of abnormally increased FDG uptake
are considered suspicious for malignant disease, particularly as metabolic changes often precede
the morphological changes associated with disease. Heterogeneity of malignant cell clones in
different sites within a single tumor and between different tumor sites in the body is a manifes‐
tation of the genomic instability that characterizes cancer cells [26]. Among the indication for
PET-CT in oncology is shown in table 4.
Tumour localisation
Pretreatment tumour staging
Prognostic stratification
Treatment monitoring
Tumour surveillance and restaging
Radiation treatment planning
Development of new anticancer drugs
Table 4. Common indications of PET-CT study
Cell 
membrane 
metabolism
Amino acid 
metabolism
Glucose 
metabolism
Figure 2. Biomarker signalling in a cell model 18F-FDG : Glucose metabolism, 18F-FET(fluoroethyltyrosine): amino acid
metabolism, 18F-FCH(18F-fluorocholine ): cell membrane metabolism
Selected Topics on Computed Tomography22
4.2. FDG PET-CT in tumor localisation
By integrating two imaging modalities encompassing the structural and functional imaging
techniques, a substantial change in the treatment planning can be achieved while reducing the
cost burden and averting futile treatment to patients. Contrasted CT technique used for the
evaluation of equivocal PET results promises higher achievable diagnostic results in the
assessment of neuroendocrine tumor with prevalence brown fat accumulation. [27]. Further‐
more, the details of the surrounding vitals structures are shown clearly on the co registered
contrasted CT image for appropriate correlation with the high metabolic focus on PET [28].
The impact of PET in detecting diffuse involvement of other organ system as part of the
metastatic spread or delineation of subcentimetre focus of FDG-avidity i.e. in melanoma has
averted futile surgery and unnecessary treatment costs (Figure 3) [2, 29]. The combined PET-
CT over scored the standalone CT and PET in the re-staging tumor after years of free-disease
survival whereby the distorted anatomy may not be easily distinguished from the site of tumor
recurrent [29]. 18[F] FDG PET-CT has been shown to be useful for detection of nodal and distant
metastases in patients with soft-tissue sarcomas compared with that at conventional imaging
[30]
4.3. FDG PET-CT in tumor staging
The evaluation of tumor prior to any treatment or surgical intervention is vital as an inappro‐
priate staging may lead to unnecessary treatment course and cost and futile surgery. Integrated
molecular imaging technique offers a high accuracy in the staging of tumor especially those
which are equivocal on the structural imaging (CT, MRI) as correlated on the clinical back‐
ground. Metabolic information by PET is always the essential element in the determination of
an altered metabolism preceding any structural change (Figure 4). There are many published
data that support this evidence in many tumor streams. A retrospective analysis included 50
patients with 55 clinical events of elevated or increasing CEA level who underwent FDG PET-
CT and MDCT for suspected tumor recurrence, FDG PET-CT has higher sensitivity than MDCT
in the identification of sites of recurrent and metastatic disease in patients with colorectal
cancer and an elevated CEA level [31]. In a study based on 172 non small cell lung carcinoma
(NSCLC) patients from a prospective clinical study who underwent diagnostic, contrast-
enhanced helical CT and integrated PET-CT on the treatment costs, the diagnostic effectiveness
in terms of correct TNM staging was 40% (31/77) for CT alone and 60% (46/77) for PET-CT. For
the assessment of resectability (tumor stages Ia-IIIa vs. IIIb-IV), 65 of 77 patients (84%) were
staged correctly by PET-CT (CT alone, 70% [54/77]). The incremental cost-effectiveness ratios
per correctly staged patient were $3,508 for PET-CT versus CT alone [32]. Data on 122 patients
with PET-CT scans as part of their initial staging of lymphoma, PET-CT upstages 17% of cases
and detects occult splenic involvement [33]
4.4. FDG PET-CT in predicting tumor aggressiveness
In addition, the degree of metabolic defect via semi quantitative analysis, standard uptake
value (SUV) could predict tumor aggressiveness and the overall patient survival as high SUV
values correlates with poor disease prognosis (Figure 5). Predicting tumor aggressiveness is
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important as early decision on the management strategy of a patient suffering from an advance
tumor could lead to an improved prognosis. A particular type of tumor i.e. thymoma which
their cellular make-up does not always exhibit malignant entity when a clinical assessment is
equivocally ascertained, the role of molecular imaging employing PET with glucose analog
has been shown to impact the prognostic outcome in many instances [34]. In a retrospective
study by Lopei et al of 91 patients with follicular lymphoma (FL), end-treatment PET-CT in
FL has high accuracy and appears to be a good predictor of progression free survival (PFS)
and patient outcome, irrespective of grading [35]. Due to clonal heterogeneity in some tumors,
FDG-PET could potentially become a determinant factor in determining which cells types may
be aggressive or have de-differentiated. In a study of 23 patients with neuroendocrine tumor
Figure 3. PET-CT restaging in 56-year-old man who had partial amputation of the right forearm for malignant mela‐
noma. The MIP-PET image shows innumerable hypermetabolic foci of metastatic lesion throughout the body (subcen‐
timetre lesions are imperceptible on the CT images; correlated CT image is not shown).
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(NET), Fathinul et al suggested a cut-off value of 9.1 to predict tumor with an aggressive
potential. This is in line with other study that suggests FDG-avid NET is usually more
aggressive than FDG-negative lesions whereby the former may be benefited from systemic
treatment (chemotherapy) [36]. In this regards, the role of molecular imaging is of prime
important when structural changes are lacking of certain valuable information of the tumor
altered cellular biology.
4.5. FDG PET-CT and the patient management
The use of PET-CT is potentially reported to change of the primary diagnosis in approximately
16% of cases, whereas PET-CT resulted in a change in staging and treatment plan in approxi‐
Figure 4. PET-CT Staging of recently diagnosed non-Hodgkin lymphoma by CT in 58-year-old woman. Coronal PET im‐
age shows involvement of the spleen (CT image was normal; correlated image is not shown) for which the disease was
upstage to stage 3.
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mately 28% to 32% of the cases, respectively (Table 5) [37]. One area in which FDG PET can
play a significant role is in establishing response to treatment [38]. Current procedures to
monitor therapy use mainly anatomical imaging modalities, such as CT, even though meta‐
bolic changes in tumors may occur earlier than, or even instead of, anatomical size changes.
A significant metabolic change can be established by comparing uptake values from pre- and
post treatment scans, although such comparisons can only be made accurately on attenuation-
corrected, quantitative PET images.
Patient (P) Histological Diagnosis AJCC (6th ed) Staging before
PET-CT Scan
AJCC (6th ed) Staging after
PET-CT Scan
P1 NPC Stage III Stage IVB
P2 NPC Stage IVB Stage IVB
P3 Ca larynx Stage I Stage I
P4 Sarcoma of tonsil Stage II
P5 Metastatic papillary carcinoma of thyroid NA Stage I
P6 Occult node-Metastatic carcinoma of neck NA FDG uptake only in
Lymph nodes
P7 Primary adnexal Ca Stage I Stage I
P8 Ca larynx Stage I Stage I
P9 Thyroglossal cyst with focal papillary
carcinoma
NA Stage III
P10 NPC Stage II Stage IVA
P11 NPC Stage I Stage I
P12 NPC Stage III Stage IVA
P13 Ca tonsil Stage IV Stage IVB
P14 Lymphoma Stage I Stage III
P15 NPC Stage I Stage I
P16 Metastatic adenocarcinoma of base of skull NA Stage IVC
P17 Ca hard palate Stage II Stage IVC
P18 NPC Stage III Stage IVB
P19 NPC Stage II Stage IVC
P20 NPC Stage II Stage IVA
P21 NPC Stage III Stage IVC
P22 NPC Stage III Stage IVC
P23 NPC Stage I Stage IVC
Table 5. Data of 23 patients with head and neck tumors on the disease staging before and after the PET-CT evaluation
(39)
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5. FDG PET-CT as a predictor of overall patient survival
The use of FDG as a ligand in particular for a molecular imaging technique i.e. PET-CT has
been shown to provide prognostic stratification. The complete metabolic response of tumor as
imaged on the FDG-PET-CT scan implies a favourable change in tumor apoptosis which is
correlated with good prognosis. In a study by Fathinul et al focusing on the esophageal tumor
as group-staged by I–IIA and IIB–IV had a 1-year survival of 50% and 25% respectively [40].
Patient with size of primary tumor (<4.5cm) had significantly (p< 0.036) better survival than
those with large size (>4.5cm). A SUVmax of > 5.5 in the primary tumor [Hazard Ratio (HR)
58.65; 95% confidence interval, p=0.032] and presence of FDG-avid lymph node (HR 20.83; p =
0.010) were strongly predictive of poor overall survival on multivariate analysis Figure (5)
Figure 5. The survival prognostication of a cohort of 18 patients with esophageal cancers as stratified by the SUVmax
cut-off of 5.5.
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6. FDG-PET-CT in coronary artery disease
Cardiovascular disease is one of the leading causes of death. It carries great impact on the
patients, their families as well as the country socially and financially. Cardiology is also a
rapidly advancing field, with new approaches to prevention, risk stratification, diagnosis and
treatment. Early detection and appropriate risk stratification will help to optimize resources
and to ensure that appropriate treatment will be provided to those who would benefit from
it. Diagnostic methods commonly used in the detection and risk stratification of coronary
artery disease include exercise stress testing, stress echocardiography, multi-slice computed
tomography, Single Photon Emission Computed Tomography (SPECT) and invasive coronary
angiography. Each of these modalities has its own advantages, disadvantages and limitations.
The management of coronary artery disease includes lifestyle modifications, medications,
percutaneous coronary interventions and coronary artery bypass surgery. Invasive procedures
carries risks, as well as its associated costs, thus it is imperative that proper selection of patients
are made based on the clinical presentation and the results of investigations. Positron Emission
Tomography is a relatively new diagnostic modality with the potential to address some of the
limitations of current commonly used diagnostic methods. Cardiology imaging using Inte‐
grated PET-CT equipment demonstrates an improved method in detecting abnormal coronary
circulation. The resolution of PET-CT images are superior than SPECT imaging as a result of
improved camera resolution and specification, high energy positron captured and CT attenu‐
ation corrected in all PET data acquisition.
In PET, 18F-FDG is the tracer most frequently used to assess myocardial viability (41-43). Since
FDG is a glucose analogue, the substance is used to evaluate cardiac glucose utilization where
mitochondria plays pivotal role in its utilization. The initial uptake in myocardial tissue is
comparable to glucose uptake. After phosphorylation, 18F FDG-6-PO4 is trapped within
cardiac tissues and the metabolism ends before the Krebs cycle enabling imaging due to the
strong signal from radiation source emitted by 18-F isotope.
Evaluation of residual glucose metabolism, a hallmark of viable myocardium, by FDG –PET
is considered the most sensitive non-invasive tool to assess the myocardial viability[ 44-45].
Viable myocardium shows preserved FDG uptake whereas, markedly reduced or absent
uptake indicates scar tissue formation (Figure 6-7). Most studies relate myocardial perfusion
to the FDG PET viability. FDG accumulates in the myocytes independent of the vascular
enrichment. Therefore quantitative assessment of the FDG concentration in the myocardium
is vital as it indicates viable tissue which is amenable to be reversed [46].
Integrated PET-CT system can be utilized in myocardial perfusion study using 82-Rubidium
(Figure 8). The dynamic data acquisition during rest and stress are quantifiable using dedicated
coronary flow quantification software (47-49). Abnormal readings will be obtained in coronary
obstruction and endothelial dysfunction using this method. Myocardial flow reserve quanti‐
fication has high sensitivity and positive predictive value in correlation with left ventricular
function (Figure 9). Thus, can be recommended as a suitable non invasive tool in making
clinical decision for managing patients with coronary artery disease
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7. FDG PET-CT in infection
FDG is a well known in-vivo biomarker indicating the rate of tissue metabolism. The initial
course of direction for clinical utility of PET-CT in oncology is now widened into the field of
infections [50-52]. Increase cancer tissue metabolism are thought to be related to raised in
surrounding inflammatory reaction as demonstrated by Kubota resulting from high accumu‐
Figure 6. The transaxial non-gated static SPECT image (1st and 2nd rows from the top) and PET-CT image (3rd and 4th
rows). There is a reversible defect seen affecting the posterior wall of left ventricle which filled up during FDG PET-CT
study in keeping with a reversible ischaemic myocardial segment.
Figure 7. The horizontal long axis non-gated static SPECT image (1st and 2nd rows from the top) and PET-CT image (3rd
row). There is an irreversible defect seen affecting the apex of left ventricle in keeping with an infarcted myocardial
segment
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lation of macrophages and granulation tissues [53]. Likewise, in infection, initial increased in
local hyperemia and capillary permeability will lead to aggregation of granulocytes, leucocytes
and macrophage at the point of entry by pathogens. This cascade of events will lead to
increased in local glucose consumption. The signals from annihilation process of positively
charged beta particles emitted from radioactive fluorinated glucose molecules in-situ will be
detected by PET camera during PET-CT imaging where the activity can be semi-quantified
using the semi-quantitative uptake value (SUV). The SUV of infective foci are often raised
above the background 18F-FDG soft tissue activity.
Despite their known clinical entity, the use of 18F-FDG PET-CT in establishing the diagnosis
of infection and inflammatory condition is still controversial. A meta analysis conducted
[54-62] from a series of review articles found that 18F-FDG demonstrate highest utility in cases
of chronic osteomyelitis, hip prostheses, diabetic foot, fever of unknown origin, vasculitis,
Figure 8. Myocardial perfusion 82-Rb demonstrating high quality images in a normal patient.
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acquired immunodeficiency syndrome, and vascular graft infection. The role of CT during
integrated PET CT imaging in the diagnosis of these conditions may range between CT for
anatomical correlation and attenuation correction to non attenuation corrected fused images.
In some condition, informations obtained from CT which may be classical and pathognomonic
can be an important adjunct features in deciding clinical management.
For example, PET using 18F-FDG appears to be a highly sensitive method in detecting infective
foci in the bone. Histologically, the 18F-FDG avidity defines the area of fibroblast proliferation
and neovascularisation with mononuclear cell infiltration at the granulation tissue formation
whereby these cells utilises most of their energy from the trapped 18F-FDG for cells metabolism
[63-65]FDG-PET is sensitive than the standalone CT in delineating evidence of implant
infection (Figure 10)
However, since artefact through beam hardening effect of X-ray from CT scan during PET-CT
study can significantly obscure the underlying pathology, often non attenuation corrected
images are being the standard reference in making clinical decision for major interventional
procedure. Thus, a combined PET-CT study can be a very useful modality in solving painful
hip problem in a patient with hip prosthesis.
18F-FDG PET-CT can also be a useful technique in ruling out infection in critically ill patients
under Intensive Care Unit (ICU) management. Study has shown that a normal scan exclude
prolonged use of antibiotic in these patients [66]. Combined CT and PET have also been
Figure 9. Quantification analysis of 82Rb Myocardial Perfusion PET CT study of a young man demonstrating normal
global stress and rest flow. The coronary reserve is normal.
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reported to be useful in detecting vascular prosthesis infection. The presence of infection in
such cases usually in elderly, will justify for removal of infected prosthesis. More recently,
Rudd et al disclosed the capability of 18F-FDG-PET-CT in identifying and quantifying vascular
inflammation within atherosclerotic plaques [67].These vulnerable plagues carry high risk of
auto detachment causing embolisation and ischaemic infarct to vital organs increasing the risk
for cerebral vascular accident and ischaemic heart disease (Figure 11). Positive correlation
between FDG uptake measurements in the left anterior descending artery with high risk factors
of coronary artery diseases has been established [68].
The scope of FDG PET-CT study is widest in cancer imaging leading to increasing application
of this powerful modality into clinical practice. There has been significant evidence showing
non exclusivity of FDG as a tumor marker observed with increase FDG uptake seen in a wide
range of infection and inflammatory conditions[69]. Examples are chronic granulomatous
infections like sarcoidoses, infections by tuberculosis, fungal infection like aspergillosis and
narcoidoses which are known to demonstrate high FDG uptake. Although they can jeopardize
the accuracy of integrated imaging interpretation in malignancy, their high standardized
uptake value (SUV) during semiquantification on FDG PET-CT can be exploited and utilized
as an important localizing tool for guided biopsy and potentially useful for navigating
response to treatment [70].
8. FDG PET-CT in pre-clinical application
PET/SPECT neuroreceptor and metabolic imaging, as well as conventional and functional MR
imaging, MR spectroscopy, optical imaging, and other techniques, is utilized almost routinely
to help establish proof of- mechanism studies for new drugs, especially at the interface between
Figure 10. Coronal CT (left panel) is insensitive in delineating implant infection as the FDG PET-CT (right panel) is clear‐
ly showing increased FDG uptake along the implant denoting underlying infection (arrow heads).
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preclinical and early phase 1 studies. In particular the use of FDG as a PET probe, its SUVmax
values have been shown to correlate with histologic grade in heterogeneous series of bone and
soft-tissue sarcomas [71]. The potential for molecular imaging in small animals to increase
knowledge of drug effects in models of human cancer has been recognized around the world.
This has been embraced as a means of decreasing the time taken to indentify agents that merit
clinical trial and to decrease the cost of drug development [72]. The ability to extrapolate from
animals to human studies makes PET a logical technique for both pre-clinical testing of new
therapeutic drugs and for the validation of new tracers that might be relevant to the evaluation
of human diseases. Manipulation of cells and tissues to produce animal models that mimic
human diseases provides a useful system to test new tracers. At a pragmatic level, a short
feedback loops between studies in mice and then in man is important. While unrestrained
proliferation has been described as a hallmark of cancer and is a target of several targeted anti-
cancer therapeutics, due to differences in blood thymidine levels and in the metabolism of PET
probe which look at cell proliferation i.e. Fluorothymidine (FLT), both uptake and excretion
of this tracer show significant differences in biodistribution in different species.
9. FDG PET-CT in non-clinical application
The development of imaging technologies, including hybrid systems allow the evaluation of
gene expression in various cancers. The underlying original genetic problems of cancer can be
Figure 11. Cross sectional image of abdominal aorta demonstrating vulnerable plague at 11 o’clock (SUVmax of 3.3)
and 3 o’clock position. The green and red cursors are shown to be crossing the centre of the aorta
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monitored by PET using radiolabeled metabolic substances including glucose, amino acids or
nucleotides. Sometimes, molecular imaging means genetic imaging or molecular-genetic
imaging in which the assessment is based on the reporter genes and labeled antisense oligo‐
nucleotide probes [73].
Radiolabeled antisense oligonucleotide probes have been applied to image endogenous gene
expression at the transcription level [74]. In diagnostic radiology, CT and ultrasonography
(US) have been examined as means of molecular-genetic imaging. In PET, dopamine 2 receptor
(D2R) gene is used as an imaging reporter gene, because of the availability of the well estab‐
lished radiolabeled probe 18F-fluoroethlspiperone (FESP) [75]. Moreover, Furukawa et al. [76]
have designed a reporter gene imaging system based on 18F-labeed estradiol and human
estrogen receptor ligand (hERL) binding domain in access of various tissues for gene therapy
monitoring.
Several researchers have investigated the use of γ-emitters for molecular imaging [77, 78];
examples include the somatostatin receptor (SSTr) 2 (SSTr2) gene and 111Inoctreotide [79], the
norepinephrine transporter gene and 131I-labeled metaiodobenzylguanidine (131I-MIBG) [80],
sodium/iodide symporter (NIS) gene and radioiodines or 99mTc-pertechnetate [33, 34]. Jacobs
et al. [81] demonstrated the first human PET image of HSV1-tk gene expression in a glioma
patient.
10. Molecular imaging: Future perspective
Molecular imaging is now being accepted by many (physicians) as an important platform in
translating genetic defect through aberrant protein function and cellular transformation and
development. Nevertheless, the sensitivity of molecular imaging techniques is varied depend‐
ing on the type of radiopharmaceutical marker used in signaling the biological processes. In
particular, the use of FDG as a ligand PET-CT has many limitations. The most obvious example
of this is in the brain where high glucose utilisation by the normal cerebral cortex can mask
brain tumors, particularly those of well differentiated. In addition, some tumors with high
metastatic potential can have relatively low FDG-uptake. Similarly, the specificity of FDG–
PET is also imperfect with some benign conditions, particularly granulomatous lesions i.e.
tuberculosis, having high FDG uptake. These very real limitations of FDG used in the molec‐
ular imaging technique have enticed the search for alternative radiotracers which signal
different biological disease process. Several alternative PET-radiopharmaceuticals are cur‐
rently being investigated, which have the potential to reveal the proliferation rate, oxygen
utilization, drug resistance properties and the viability of the tumors. Examples of new PET
tracers include fluoroethyltyrosine (FET) for brain tumor imaging; the proliferation marker
18F-fluorothymidine (FLT) to assess bone marrow reserves and the exploitation of dual tracer
strategy i.e. FDG and 68 Ga DOTA –octreotate for staging and therapeutic response in
neuroendocrine tumor would promise a more complete assessment of disease process and
tumor biology. The choline analogue 18F-fluorocholine (FCH) for patients with rising prostate
specific antigen levels would potentially have an impact on the management strategy and thus
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improve the overall patient survival. It is likely that the continuing success of molecular
imaging will rest on the future development of more disease specific ligand or tracer, used in
specific combination to answer the important clinical question.
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